Abstract Background Anthracyclines are a mainstay of chemotherapy. However. a relatively frequent adverse outcome of anthracycline treatment is cardiomyopathy. Multiple genetic studies have begun to dissect the complex genetics underlying cardiac sensitivity to the anthracycline drug class. https://www.markbroyard.com/